Register | Forgot password?
Switch to Arabic
Saturday, November 28 - 2009

Ascent's Farley stresses importance of venture capital funds for regional economies

  • United Arab Emirates: Wednesday, November 15 - 2006 at 14:04
  • PRESS RELEASE

Venture capital funding is crucial for the Middle East in order to build longevity in its economy, according to medical investment specialist, Peggy Farley, one of the General Partners in the Ascent Medical Technology Fund II.

Article continues below
  • Peggy Farley.
    Peggy Farley.
"The Middle East is recognised as one of the top emerging research markets in the world," said Farley, who will be part of a round table discussion at the Middle East Capital Markets 2006 conference in Dubai later this month (20-21 November 2006).

"For regional economies to grow further and sustain strength and longevity, they should embrace venture capital funding and look at it as a critical tool for the future of the nations, rather than just focusing on building short-term wealth," she added.

In 2005, US-based Ascent Group launched the $100 million Ascent Medical Technology Fund II, a first-of-its-kind private equity vehicle in the region aimed at promoting the development of the Middle East medical technology industry.

Ascent is now working towards providing venture capital in the region to advance medical innovation and research in the Middle East.

According to Farley, venture capital is considered as a form of capital typically provided by outside investors for the financing of new growing businesses.

"Venture capital investments generally are high risk but offer the potential for above average returns.

"It is a phenomenon most closely associated with the US and technologically innovative ventures. However, the Middle East is at a critical point in its development, with investors from the region and beyond increasingly seeking fresh ways to finance opportunities," she said.

"The Middle East can be a centre for intellectual property and advances in the medical technology sector if funds are diverted into developing clinical research facilities and medical technology manufacturing facilities," Farley concluded.

Medical technology investments are characterised by their outstanding performance. The Ascent medical technology investments have had an average return on investments (ROI) of 824 per cent year on year, against an average of 100 per cent from traditional equity and capital markets.

The Ascent Medical Technology Fund II fund will have a 10-year life, and Ascent expects to launch another in two years.
Also consider reading:
Log in to request more information from Ascent Group

Notes and media contacts

For further information:

Euro RSCG Furness for Ascent Technologies
Hisham El Masri
Tel +9714 3903030
Fax +9714 3918486

The Ascent Medical Technology Fund II, L.P. (the Fund) is being established by Ascent Private Equity II LLC to make privately negotiated investments in seed, early and mezzanine stage growth companies principally in the medical device industry and, to a lesser extent, in other medical technology industries.
To diversify access to scientific innovation, enhance the profitability of investments, and streamline proof of clinical efficacy, the Fund will be involving certain emerging markets in growing the companies in which the Fund invests.
All Fund investments will avail themselves of opportunities that exist in selected emerging economies for clinical research, manufacturing, and intellectual property. This objective will be achieved either by (1) investing in US companies which will in turn invest in joint ventures or wholly owned subsidiaries located in developing countries; or, (2) by establishing businesses directly in emerging markets.
The Fund is seeking to raise aggregate capital commitments of $100 million. The minimum commitment is $1 million for individual investors and $5 million for institutional investors. A first closing will take place when the Fund has raised a minimum of $30 million of aggregate commitments.

Fund II is a Delaware Limited Partnership. The General Partner, a Delaware Limited Liability Company, has established in Bahrain a Feeder Fund Company that is a Limited Partner of the Fund. The Bahrain Company is for those non-US investors who do not wish to invest directly into the US Fund.

The Principals of the General Partner managed Ascent Medical Technology Fund, L.P. ("Fund I") and Ascent Private Equity, LLC, established, respectively in 2000 and 1999. The advisor to the Fund, Ascent Capital Management Inc., is a US Securities and Exchange Commission Registered Investment Advisory firm. Fund I is more than 75 per cent invested, thus, enabling the principals of the General Partner to develop the Fund. Fund I has seen two harvests. The ROI is in excess of 240 per cent. All of Fund I's other investments are operating; many have seen tremendous success since the time Fund I invested in them.

Disclaimer:

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions